Publication|Articles|January 21, 2026
Supplements and Featured Publications
- Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran
Participating Faculty: Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran
Listen
0:00 / 0:00
Advertisement
Faculty
Steven W. Pipe, MD
Professor of Pediatrics and Pathology
University of Michigan
Ann Arbor, MI
Faculty Disclosures
The following have relevant commercial financial relationships or affiliations to disclose:
Steven W. Pipe, MD, reports the following relevant commercial financial relationships or affiliations in the past 12 months:
CONSULTANCIES OR PAID ADVISORY BOARDS
Bayer, BioMarin, Chugai, CSL Behring, HEMA Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Roche/Genentech/Spark Therapeutics, Sanofi, Star Therapeutics, and Takeda
LECTURE FEES AT THE INVITATION OF A COMMERCIAL SPONSOR
Chugai, Roche, Sanofi
MEETING/CONFERENCE ATTENDANCE
Sanofi
SCIENTIFIC ADVISORY BOARDS
Equilibra, GeneVentiv
Articles in this issue
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
5
